中国P站

Organ donation; Opt-out policy; Presumed consent; Organ shortage; Transplant rates; Public health policy; Donor legislation; Europe; Ethical considerations; Donation system reform

Introduction

Organ transplantation remains one of the most effective treatments for end-stage organ failure, significantly improving survival and quality of life. However, the persistent global shortage of donor organs continues to limit access to life-saving procedures [1-5]. In response, many countries have sought legislative reforms to increase donation rates, most notably by shifting from an opt-in (explicit consent) model to an opt-out (presumed consent) system. Under opt-out policies, individuals are presumed to be organ donors unless they have formally registered an objection. Europe has been at the forefront of adopting opt-out systems, with countries like Spain, Belgium, Austria, and more recently, England, implementing such models. This review examines the real-world outcomes of opt-out policies across various European nations and assesses their effectiveness in increasing donation rates, improving transplant outcomes, and shaping public trust and ethical dialogue [6-10].

Discussion

The implementation of opt-out organ donation policies across Europe has generated substantial interest and debate. Spain, often cited as the global leader in organ donation, adopted a soft opt-out model in 1979, wherein family members are still consulted despite presumed consent. This model, combined with a strong national transplant coordination system (ONT) and hospital-based transplant coordinators, has led to a sustained increase in donation rates, currently exceeding 45 donors per million population (pmp)—the highest in the world.

Belgium and Austria, both early adopters of hard opt-out systems, also report donation rates of over 30 donors pmp, with minimal family override allowed. The evidence from these nations suggests that opt-out legislation alone is not sufficient, but when paired with robust infrastructure, public awareness campaigns, and well-trained healthcare professionals, it creates a conducive environment for increasing organ availability.

In contrast, countries like France and Wales, which more recently introduced opt-out systems, have shown incremental gains. Wales, which moved to presumed consent in 2015, saw a 49% increase in consent rates over five years, though the total number of actual donors fluctuated due to other logistical factors such as donor eligibility and hospital readiness.

One of the most debated aspects of opt-out systems is the ethical tension between autonomy and presumed consent. While presumed consent increases donation potential, it raises questions about whether individuals are adequately informed and whether silence equates to true consent. Public education and clear opt-out mechanisms are essential to uphold ethical standards and public trust.

The impact of opt-out systems has also been studied in the context of family override. Even in presumed consent countries, families are often approached and given the option to affirm or oppose donation. Countries with high public awareness and transparent policies report lower family refusal rates, highlighting the importance of sustained communication and trust-building.

Economic models have also assessed the cost-effectiveness of opt-out systems, showing that even modest increases in donation rates significantly reduce costs associated with long-term dialysis in kidney failure and hospital care in liver or heart failure. Policymakers have therefore endorsed opt-out as both a public health and economic priority.

However, not all countries have seen immediate success. Greece and Poland, despite adopting opt-out laws, continue to face low donation rates due to weak transplant infrastructure, lack of hospital coordination, and limited public engagement—reinforcing that law must be supported by system-level investment.

Conclusion

Opt-out organ donation policies have demonstrated positive impacts on donation and transplant rates in many European countries, especially when implemented alongside strong infrastructure, healthcare professional training, and public education. Spain’s success illustrates that presumed consent, while important, is most effective when integrated into a broader system of donation promotion and management. Ethical considerations, particularly regarding individual autonomy and family involvement, must be addressed through transparent policy, accessible opt-out registries, and public trust. For nations struggling with organ shortages, opt-out systems represent a promising legislative tool, but their effectiveness ultimately depends on systemic support, cultural alignment, and sustained community engagement.

References

1. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 3:1112-1119.

   Indexed at, Google Scholar, Crossref

2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) Heart transplant program at IRCCS-ISMETT: Impact of mechanical circulatory support on pre- and post -transplant survival. Int J Cardiol 219: 358-361.

   Indexed at, Google Scholar, Crossref

3. Zieli艅ska K, Kukulski L, Wróbel M, Przyby艂owski P, Rokicka D, et al. (2022) Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT). Ann Transplant 27: 933420.

   Indexed at, Google Scholar, Crossref

4. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 33: 241-251.

   Indexed at, Google Scholar, Crossref

5. R D Vanderlaan, C Manlhiot, L B Edwards, J Conway, B W McCrindle, et al. (2015) Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant 19: 896-905.

   Indexed at, Google Scholar, Crossref

6. Kitamura S (2012) Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 60: 639-644.

   Indexed at, Google Scholar, Crossref

7. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 36: 407-417.

   Indexed at, Google Scholar, Crossref

8. Saczkowski R, Dacey C, Bernier PL (2010) Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival. Interact Cardiovasc Thorac Surg 10: 1026-1033.

   Indexed at, Google Scholar, Crossref

9. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg 147: 462-468.

   Indexed at, Google Scholar, Crossref

10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant 36: 13-18.

    Indexed at, Google Scholar, Crossref